EBITDA up 34% yoy
Lumibird''s EBITDA was EUR32.4m, up 34% yoy and 5% above consensus. This performance was driven by the gross margin uplift (+EUR15.6m) notably due to product mix and the roll-out of commercial synergies within the medical division. Operating leverage was also supported by the strict control of opex with personnel expenses increasing modestly.
Medical driving the EBITA margin improvement
By division, the performance was particularly impressive in medical with the EBITDA mar ....
18 Mar 2022
Promising results, robust outlook
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Promising results, robust outlook
EBITDA up 34% yoy
Lumibird''s EBITDA was EUR32.4m, up 34% yoy and 5% above consensus. This performance was driven by the gross margin uplift (+EUR15.6m) notably due to product mix and the roll-out of commercial synergies within the medical division. Operating leverage was also supported by the strict control of opex with personnel expenses increasing modestly.
Medical driving the EBITA margin improvement
By division, the performance was particularly impressive in medical with the EBITDA mar ....